Better Healthcare Stock to Own in a Recession: Defensive or Growth?

Key numbers: CVS beta 0.46 and Johnson & Johnson beta 0.33, implying roughly 4.6% and 3.3% declines if the market drops 10%. The Iran conflict and related Strait of Hormuz disruptions raise recession and inflation risks (energy and food prices), which could increase investor demand for defensive, low-beta healthcare large caps that also pay dividends. The article contrasts that defensive strategy with a high-risk/high-reward approach in small- and mid-cap biotech (examples: Grail/GRAL and Viking/VKTX), noting Grail’s follow-up NHS data could be decisive and Viking has phase-3/maintenance oral results due in Q3 2026. Motley Fool’s Stock Advisor did not include JNJ in its current top-10 recommendations (disclosed).

Analysis

Geopolitical stress centered on the Strait of Hormuz amplifies an inflationary pathway that selectively compresses margins: shipping and energy-driven input cost shocks disproportionately hurt asset-light generics and small medtech OEMs that operate on thin gross margins and long lead-times. By contrast, vertically integrated healthcare franchises (payer/PBM + retail) are positioned to reprice flows or shift care-site mix, creating a tactical window where scale and contracting leverage earn optionality versus market-cap peers.

Binary biotechs introduce idiosyncratic returns that are largely orthogonal to macro cycles, producing useful portfolio convexity if sized and hedged. GRAL’s prior primary miss implies that follow-up datasets carry skewed distributions — downside is immediate and high-probability while upside is concentrated and delayed; Viking’s VKTX carries a nearer-term operational catalyst path (maintenance/oral strategy) with identifiable clinical design fixes, making structured long exposure more attractive than outright stock punts.

Putting these dynamics together, the efficient approach is a two‑bucket trade: a core defensive sleeve financed in part by selling optionality into oversized demand for recession insurance, and a small, hedged satellite of binary biotech option structures sized to absorb major winners. The implicit risk is regime flip: a rapid resolution of the geopolitical shock or a sudden market risk-on would punish low-beta sheltering and elevate opportunity cost of capital for long-duration biotechs within 1–3 months.

Key Decisions for Investors

• Core defensive sleeve (3–6% portfolio): Buy JNJ and CVS equal-weight for 3–12 months exposure; finance 30–50% of position cost by selling 6–9 month 10–15% OTM covered calls to capture premium and lower entry basis. Risk/Reward: limited upside ceding due to sold calls; downside cushioned by dividends and low-beta profile—max drawdown roughly capped to market correlation over a 3–12 month recession window.
• Satellite biotech convexity (1–2% portfolio): Long-dated call spreads on VKTX sized to 1–2% notional with expiries covering mid-2026 catalysts (e.g., 12–18 month expiries). Structure as debit call spread to cap premium; target 3x–10x payoff if Phase 3/maintenance readouts validate tolerability; max loss = premium paid.
• Dispersion pair (0.5–1% portfolio): Short GRAL via put spread (6–12 month expiries) or buy OTM puts and sell further OTM puts to fund cost, paired 1:1 with long VKTX exposure. Rationale: monetize high implied volatility and asymmetric probability after primary miss; Reward: premium capture and limited capital at risk; Risk: follow-up positive readout could cause sharp short-squeeze—cap position size accordingly.
• Tactical hedge / funding tactic (0.5–1% portfolio): If deploying the above, sell index or sector tail risk via buying S&P 500 3–6 month puts financed by selling short-dated calls on the defensive sleeve (JNJ/CVS) to keep net hedging cost neutral. This maintains downside protection for the satellite biotech bets while monetizing elevated demand for low-beta shelter; monitor geopolitical headlines—close if Brent or regional shipping insurance indicators normalize within 30–60 days.